Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ANI, IDT Ink U.S. Generic Commercialization Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

ANI, IDT Ink U.S. Generic Commercialization Pact

ANI expands marketed generic product portfolio

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ANI Pharmaceuticals, Inc. has entered an agreement with IDT Australia, Ltd. to commercialize as many as 18 marketed U.S. generic drug products. ANI paid $1.0 million for exclusive rights to the North American market and will share in a percentage of profits upon commercialization. The total current annual U.S. market for these products is $538 million according to IMS Health. 
 
Arthur S. Przybyl, president and chief executive officer of ANI Pharmaceuticals, stated, “This partnership represents a substantial opportunity for ANI to further expand our marketed generic product portfolio. We are excited to establish this relationship with a high quality global generic manufacturer such as IDT.”
 
Dr. Paul MacLeman, managing director and chief executive officer of IDT, said, “In many ways ANI is an ideal US partner for IDT as it has a proven track record having already successfully commercialized its own generic drugs, is nimble and shares IDT’s zest for growth. Culturally the two companies are a good fit and the terms of the agreement are fair to both parties. We are very much looking forward to working with the ANI team to grow sales and create value.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters